Clinical Study Uses in DEFINITIONS Clause

DEFINITIONS from License Agreement

THIS LICENSE AGREEMENT (this Agreement) is made as of April 25, 2013, (Effective Date), by and between KINEX PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 701 Ellicott Street, Buffalo, New York 14203, USA (Kinex) and ZENRX LIMITED, a corporation existing under the laws of New Zealand and having its principal office at 156 Frederick Street, PO Box 1777, Dunedin 9054, New Zealand (ZenRx).

DEFINITIONS. Unless specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, shall have the respective meanings set forth below: 1.1 Act means the United States Food, Drug, and Cosmetic Act of 1938, as amended, and the rules and regulations promulgated thereunder, or any successor act, as the same shall be in effect from time to time. *** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 1.2 Affiliate means with respect to a Party (a) any corporation or business entity of which more than fifty percent (50%) of the securities or other ownership interests representing the equity, the voting stock or general partnership interest are owned, controlled or held, directly or indirectly, by a Party; (b) any corporation or business entity which, directly or indirectly, owns, controls or holds more than fifty percent (50%) (or the maximum ownership interest permitted by law) of the securities or other ownership interests representing the equity, voting stock or general partnership interest of a Party; (c) any corporation or business entity of which, directly or indirectly, an entity described in the immediately preceding subsection (b) controls or holds more than fifty percent (50%) (or the maximum ownership interest permitted by law) of the securities or other ownership interests representing the equity, voting stock or general partnership interest of such corporation or entity; or (d) any corporation or business entity of which a Party has the right to acquire, directly or indirectly, more than fifty percent (50%) of the securities or other ownership interests representing the equity, voting stock or general partnership interest thereof. 1.3 Agreement Term has the meaning set forth in Section 8.1(a). 1.4 Breaching Party has the meaning set forth in Section 8.2(b). 1.5 Business Day means any calendar day, except that if an activity to be performed or an event to occur falls on a Saturday, Sunday or a day which is recognized as a national holiday in the place of performance of an applicable activity or occurrence of an applicable event, then the activity may be performed or the event may occur on the next day that is not a Saturday, Sunday or nationally recognized holiday. *** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 1.6 Calendar Quarter means for each Calendar Year, each of the three (3) month periods ending on March 31, June 30, September 30 and December 31; provided, however, (i) that the first Calendar Quarter of any period specified under this Agreement shall extend from the commencement of such period to the end of the first complete Calendar Quarter thereafter; and (ii) the last Calendar Quarter shall end upon the expiration or termination of this Agreement. 1.7 Calendar Year means, for the year of execution of this Agreement, the period commencing on the Effective Date and ending on December 31, 2013, and for each year thereafter, each successive period beginning on January 1 and ending twelve (12) consecutive calendar months later on December 31. 1.8 CFR means the United States Code of Federal Regulations. 1.9 cGMP means current good manufacturing practices. 1.10 Claims has the meaning set forth in Section 9.2. 1.11 Clinical Study(ies) means any clinical study of a Licensed Product conducted on humans. 1.12 Commercialize or Commercialization means promotion, marketing, sale, supply, manufacture, import, export and distribution of Licensed Products, including any educational or pre-launch activities. 1.13 Commercially Reasonable Efforts means exerting such efforts and employing such resources as would normally be exerted or employed by a Party for its other drug candidates and pharmaceutical products of a comparable stage of development and commercial potential; and for this Agreement, with respect to Regulatory Approval and First Commercial Sale of Licensed Product, means (i) Completion by ZenRx of one or more Clinical Study(ies) in New Zealand with a minimum of eighty *** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. (80) patients (and projected to be up to one hundred twenty (120) patients for Clinical Studies for both Oraxol and Oratecan) within four (4) years after the approval of the study plan approved by the Steering Committee (Clause 3.2), (ii) filing of an application for Regulatory Approval in New Zealand within four (4) years after the approval of the study plan approved by the Steering Committee (Clause 3.2), and filing of an application for Regulatory Approval in Australia within 12 months of receiving the US or EU application dossier, (iii) achieving First Comme

DEFINITIONS from License Agreement

THIS LICENSE AGREEMENT (this Agreement) is made as of May 6th, 2012, by and between KINEX PHARMACEUTICALS, LLC, a limited liability company organized and existing under the laws of the State of Delaware USA and having its principal office at 701 Ellicott Street, Buffalo, New York 14203, USA (Kinex) and GUANGZHOU XIANGXUE NEW DRUG DISCOVERY AND DEVELOPMENT COMPANY LIMITED, a Chinese company existing under the laws of China and having its principal office at 2 Jinfengyuan Road, Guangzhou, CHINA 510663 (XPH).

DEFINITIONS. Unless specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, shall have the respective meanings set forth below: 1.1 Act means the United States Food, Drug, and Cosmetic Act of 1938, as amended, and the rules and regulations promulgated thereunder, or any successor act, as the same shall be in effect from time to time. *** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 1.2 Affiliate means with respect to a Party (a) any corporation or business entity of which more than fifty percent (50%) of the securities or other ownership interests representing the equity, the voting stock or general partnership interest are owned, controlled or held, directly or indirectly, by a Party; (b) any corporation or business entity which, directly or indirectly, owns, controls or holds more than fifty percent (50%) (or the maximum ownership interest permitted by law) of the securities or other ownership interests representing the equity, voting stock or general partnership interest of a Party; (c) any corporation or business entity of which, directly or indirectly, an entity described in the immediately preceding subsection (b) controls or holds more than fifty percent (50%) (or the maximum ownership interest permitted by law) of the securities or other ownership interests representing the equity, voting stock or general partnership interest of such corporation or entity; or (d) any corporation or business entity of which a Party has the right to acquire, directly or indirectly, more than fifty percent (50%) of the securities or other ownership interests representing the equity, voting stock or general partnership interest thereof 1.3 Agreement Term has the meaning set forth in Section 9.1(a). 1.4 Breaching Party has the meaning set forth in Section 9.2(b). 1.5 Business Day means any calendar day, except that if an activity to be performed or an event to occur falls on a Saturday, Sunday or a day which is recognized as a national holiday in the place of performance of an applicable activity or occurrence of an applicable event, then the activity may be performed or the event may occur on the next day that is not a Saturday, Sunday or nationally recognized holiday. *** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 1.6 Calendar Quarter means for each Calendar Year, each of the three (3) month periods ending on March 31, June 30, September 30 and December 31; provided, however, that (i) the first Calendar Quarter of any period specified under this Agreement shall extend from the commencement of such period to the end of the first complete Calendar Quarter thereafter; and (ii) the last Calendar Quarter shall end upon the expiration or termination of this Agreement. 1.7 Calendar Year means, for the first Calendar Year, the period commencing on the Effective Date and ending on December 31, 2012, and for each year thereafter, each successive period beginning on January 1 and ending twelve (12) consecutive calendar months later on December 31. 1.8 CFR means the United States Code of Federal Regulations. 1.9 cGMP means current good manufacturing practices. 1.10 Claims has the meaning set forth in Section 10.2. 1.11 Clinical Studies means any clinical studies of a Licensed Product conducted on humans. 1.12 Commercialize or Commercialization means promotion, marketing, sale, supply, manufacture, import, export and distribution of Licensed Products, including any educational or prelaunch activities. 1.13 Commercially Reasonable Efforts means exerting such efforts and employing such resources as would normally be exerted or employed by a Party for its other drug candidates and pharmaceutical products of a comparable stage of development and commercial potential and this includes all the milestones described in Article 4. *** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 1.14 Completion means, with respect to any Clinical Study, the completion of treatment for the necessary number of patients required by the applicable protocol and completion of the statistical analysis of the study data. 1.15 Compound means KX-02 (also known as KX2- 361) that cannot be developed, manufactured, used, sold, offered for sale, or imported without infringing one or more valid claims of the Intellectual Property related to the Compound and the Licensed Product, as diagrammed on Schedule 1.1 attached hereto, and any pharmaceutically acceptable salts, hydrates, solvates, and prodrugs of the foregoing, or mixtures thereof. 1.16 Control means possession of the ability to grant the rights and licenses as provided for here

DEFINITIONS from License Agreement

THIS LICENSE AGREEMENT (this Agreement) is made as of May 6th, 2012, by and between KINEX PHARMACEUTICALS, LLC, a limited liability company organized and existing under the laws of the State of Delaware USA and having its principal office at 701 Ellicott Street, Buffalo, New York 14203, USA (Kinex) and GUANGZHOU XIANGXUE NEW DRUG DISCOVERY AND DEVELOPMENT COMPANY LIMITED, a Chinese company existing under the laws of China and having its principal office at 2 Jinfengyuan Road, Guangzhou, CHINA 510663 (XPH).

DEFINITIONS. Unless specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, shall have the respective meanings set forth below: 1.1 Act means the United States Food, Drug, and Cosmetic Act of 1938, as amended, and the rules and regulations promulgated thereunder, or any successor act, as the same shall be in effect from time to time. *** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 1.2 Affiliate means with respect to a Party (a) any corporation or business entity of which more than fifty percent (50%) of the securities or other ownership interests representing the equity, the voting stock or general partnership interest are owned, controlled or held, directly or indirectly, by a Party; (b) any corporation or business entity which, directly or indirectly, owns, controls or holds more than fifty percent (50%) (or the maximum ownership interest permitted by law) of the securities or other ownership interests representing the equity, voting stock or general partnership interest of a Party; (c) any corporation or business entity of which, directly or indirectly, an entity described in the immediately preceding subsection (b) controls or holds more than fifty percent (50%) (or the maximum ownership interest permitted by law) of the securities or other ownership interests representing the equity, voting stock or general partnership interest of such corporation or entity; or (d) any corporation or business entity of which a Party has the right to acquire, directly or indirectly, more than fifty percent (50%) of the securities or other ownership interests representing the equity, voting stock or general partnership interest thereof 1.3 Agreement Term has the meaning set forth in Section 9.1(a). 1.4 Breaching Party has the meaning set forth in Section 9.2(b). 1.5 Business Day means any calendar day, except that if an activity to be performed or an event to occur falls on a Saturday, Sunday or a day which is recognized as a national holiday in the place of performance of an applicable activity or occurrence of an applicable event, then the activity may be performed or the event may occur on the next day that is not a Saturday, Sunday or nationally recognized holiday. *** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 1.6 Calendar Quarter means for each Calendar Year, each of the three (3) month periods ending on March 31, June 30, September 30 and December 31; provided, however, that (i) the first Calendar Quarter of any period specified under this Agreement shall extend from the commencement of such period to the end of the first complete Calendar Quarter thereafter; and (ii) the last Calendar Quarter shall end upon the expiration or termination of this Agreement. 1.7 Calendar Year means, for the first Calendar Year, the period commencing on the Effective Date and ending on December 31, 2012, and for each year thereafter, each successive period beginning on January 1 and ending twelve (12) consecutive calendar months later on December 31. 1.8 CFR means the United States Code of Federal Regulations. 1.9 cGMP means current good manufacturing practices. 1.10 Claims has the meaning set forth in Section 10.2. 1.11 Clinical Studies means any clinical studies of a Licensed Product conducted on humans. 1.12 Commercialize or Commercialization means promotion, marketing, sale, supply, manufacture, import, export and distribution of Licensed Products, including any educational or prelaunch activities. 1.13 Commercially Reasonable Efforts means exerting such efforts and employing such resources as would normally be exerted or employed by a Party for its other drug candidates and pharmaceutical products of a comparable stage of development and commercial potential and this includes all the milestones described in Article 4. *** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 1.14 Completion means, with respect to any Clinical Study, the completion of treatment for the necessary number of patients required by the applicable protocol and completion of the statistical analysis of the study data. 1.15 Compound means KX-02 (also known as KX2- 361) that cannot be developed, manufactured, used, sold, offered for sale, or imported without infringing one or more valid claims of the Intellectual Property related to the Compound and the Licensed Product, as diagrammed on Schedule 1.1 attached hereto, and any pharmaceutically acceptable salts, hydrates, solvates, and prodrugs of the foregoing, or mixtures thereof. 1.16 Control means possession of the ability to grant the rights and licenses as provided for here

DEFINITIONS from License Agreement

THIS LICENSE AGREEMENT (this Agreement) is made as of April 25, 2013, (Effective Date), by and between KINEX PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 701 Ellicott Street, Buffalo, New York 14203, USA (Kinex) and ZENRX LIMITED, a corporation existing under the laws of New Zealand and having its principal office at 156 Frederick Street, PO Box 1777, Dunedin 9054, New Zealand (ZenRx).

DEFINITIONS. Unless specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, shall have the respective meanings set forth below: 1.1 Act means the United States Food, Drug, and Cosmetic Act of 1938, as amended, and the rules and regulations promulgated thereunder, or any successor act, as the same shall be in effect from time to time. *** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 1.2 Affiliate means with respect to a Party (a) any corporation or business entity of which more than fifty percent (50%) of the securities or other ownership interests representing the equity, the voting stock or general partnership interest are owned, controlled or held, directly or indirectly, by a Party; (b) any corporation or business entity which, directly or indirectly, owns, controls or holds more than fifty percent (50%) (or the maximum ownership interest permitted by law) of the securities or other ownership interests representing the equity, voting stock or general partnership interest of a Party; (c) any corporation or business entity of which, directly or indirectly, an entity described in the immediately preceding subsection (b) controls or holds more than fifty percent (50%) (or the maximum ownership interest permitted by law) of the securities or other ownership interests representing the equity, voting stock or general partnership interest of such corporation or entity; or (d) any corporation or business entity of which a Party has the right to acquire, directly or indirectly, more than fifty percent (50%) of the securities or other ownership interests representing the equity, voting stock or general partnership interest thereof. 1.3 Agreement Term has the meaning set forth in Section 8.1(a). 1.4 Breaching Party has the meaning set forth in Section 8.2(b). 1.5 Business Day means any calendar day, except that if an activity to be performed or an event to occur falls on a Saturday, Sunday or a day which is recognized as a national holiday in the place of performance of an applicable activity or occurrence of an applicable event, then the activity may be performed or the event may occur on the next day that is not a Saturday, Sunday or nationally recognized holiday. *** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 1.6 Calendar Quarter means for each Calendar Year, each of the three (3) month periods ending on March 31, June 30, September 30 and December 31; provided, however, (i) that the first Calendar Quarter of any period specified under this Agreement shall extend from the commencement of such period to the end of the first complete Calendar Quarter thereafter; and (ii) the last Calendar Quarter shall end upon the expiration or termination of this Agreement. 1.7 Calendar Year means, for the year of execution of this Agreement, the period commencing on the Effective Date and ending on December 31, 2013, and for each year thereafter, each successive period beginning on January 1 and ending twelve (12) consecutive calendar months later on December 31. 1.8 CFR means the United States Code of Federal Regulations. 1.9 cGMP means current good manufacturing practices. 1.10 Claims has the meaning set forth in Section 9.2. 1.11 Clinical Study(ies) means any clinical study of a Licensed Product conducted on humans. 1.12 Commercialize or Commercialization means promotion, marketing, sale, supply, manufacture, import, export and distribution of Licensed Products, including any educational or pre-launch activities. 1.13 Commercially Reasonable Efforts means exerting such efforts and employing such resources as would normally be exerted or employed by a Party for its other drug candidates and pharmaceutical products of a comparable stage of development and commercial potential; and for this Agreement, with respect to Regulatory Approval and First Commercial Sale of Licensed Product, means (i) Completion by ZenRx of one or more Clinical Study(ies) in New Zealand with a minimum of eighty *** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. (80) patients (and projected to be up to one hundred twenty (120) patients for Clinical Studies for both Oraxol and Oratecan) within four (4) years after the approval of the study plan approved by the Steering Committee (Clause 3.2), (ii) filing of an application for Regulatory Approval in New Zealand within four (4) years after the approval of the study plan approved by the Steering Committee (Clause 3.2), and filing of an application for Regulatory Approval in Australia within 12 months of receiving the US or EU application dossier, (iii) achieving First Comme

DEFINITIONS from License Agreement

THIS LICENSE AGREEMENT (the Agreement), effective as of July 31, 2013 (the Effective Date), is by and between Argos Therapeutics, Inc., a corporation organized and existing under the laws of Delaware (Argos) and Green Cross Corp., a corporation organized and existing under the laws of Republic of Korea (Green Cross).

DEFINITIONS. Unless specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, shall have the respective meanings set forth below: 1.1 Affiliate means a corporation or non-corporate business entity that, directly or indirectly, controls, is controlled by, or is under common control with the Person specified, for so long as such control continues. An entity will be regarded as in control of another entity if: (a) it owns, directly or indirectly, at least 50% of the voting securities or capital stock of such entity, or has other comparable ownership interest with respect to any entity other than a corporation; or (b) it possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of the corporation or non-corporate business entity, as applicable, whether through the ownership or control of voting securities, by contract or otherwise. 1.2 Argos Data means all clinical data that is produced or generated by Argos or its Related Parties during a Clinical Study for the Licensed Product. 1.3 Argos Indemnitees has the meaning set forth in Section 7.5.1. 1.4 Argos In-License means an agreement between Argos and a Third Party pursuant to which Argos has rights and obligations with respect to, or which otherwise Cover, the Licensed Product and is necessary to Develop, Commercialize and/or Manufacture the Licensed Product in the Field in the Green Cross Territory, including without limitation, the Existing Argos In-Licenses. 1.5 Argos Know-How means Know-How Controlled by Argos during the Term that is not in the public domain and is reasonably necessary or useful for Green Cross and its Related Parties to perform their obligations or exploit their rights under this Agreement with respect to products incorporating Argos Arcelis Personalized Immunotherapy Platform for the treatment of mRCC, as such platform is more particularly described on Schedule A attached hereto. For the avoidance of doubt, Argos Know-How shall include Argos Data, but shall not include any Know-How associated with or relating to Automated Systems, dendritic cell transfected with IL4 RNA for the treatment of unwanted autoimmune responses, anti-interferon alpha antibodies, soluble CD83 or regulatory T cells. 1.6 Argos Patent Rights means those Patent Rights Controlled by Argos during the Term that relate to Argos Arcelis Personalized Immunotherapy Platform for the treatment of mRCC and that are reasonably necessary or useful for Green Cross and its Related Parties to perform their obligations or exploit their rights under this Agreement with respect to the Licensed Product in the Field in the Green Cross Territory, including without limitation, any foreign counterparts in the Green Cross Territory to the Patent Rights set forth in Schedule B of this Agreement. For the avoidance of doubt, Argos Patent Rights shall not include patent rights associated with or relating to Automated Systems, dendritic cell transfected with IL4 RNA for the treatment of unwanted autoimmune responses, anti-interferon alpha antibodies, soluble CD83 or regulatory T cells. 1.7 Argos Technology means, collectively, Argos Know-How and Argos Patent Rights. 1.8 Argos Territory means all countries of the world other than the Green Cross Territory. 1.9 Argos Trademark has the meaning set forth in Section 8.8.2. 1.10 Automated Systems means the automated cellular and RNA systems used from time to time to Manufacture the Licensed Product, as such systems are generally described in Schedule C attached hereto. 1.11 Bankrupt Party has the meaning set forth in Section 9.2.3(c). 1.12 Calendar Quarter means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31; provided, that (a) the first Calendar Quarter of the Term shall begin on the Effective Date and end on the first to occur of March 31, June 30, September 30 or December 31 thereafter and the last Calendar Quarter of the Term shall end on the last day of the Term and (b) the first Calendar Quarter of the Royalty Term shall begin on the First Commercial Sale of the Licensed Product and end on the first to occur of March 31, June 30, September 30 or December 31 thereafter and the last Calendar Quarter of the Royalty Term shall end on the last day of such Royalty Term. 1.13 Calendar Year means each successive period of twelve (12) months commencing on January 1 and ending on December 31; provided, that (a) the first Calendar Year of the Term shall begin on the Effective Date and end on the first December 31 thereafter and the last Calendar Year of the Term shall end on the last day of the Term and (b) the first Calendar Year of the Royalty Term shall begin on the First Commercial Sale of the Licensed Product and end on the first December 31 thereafter and the last Calendar Year of the Term shall end on the last day of the Royalty Term. 1.14 Clinical Data means Argos Data and/or Green Cross

DEFINITIONS from License Agreement

THIS LICENSE AGREEMENT (the Agreement), effective as of July 31, 2013 (the Effective Date), is by and between Argos Therapeutics, Inc., a corporation organized and existing under the laws of Delaware (Argos) and Green Cross Corp., a corporation organized and existing under the laws of Republic of Korea (Green Cross).

DEFINITIONS. Unless specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, shall have the respective meanings set forth below: 1.1 Affiliate means a corporation or non-corporate business entity that, directly or indirectly, controls, is controlled by, or is under common control with the Person specified, for so long as such control continues. An entity will be regarded as in control of another entity if: (a) it owns, directly or indirectly, at least 50% of the voting securities or capital stock of such entity, or has other comparable ownership interest with respect to any entity other than a corporation; or (b) it possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of the corporation or non-corporate business entity, as applicable, whether through the ownership or control of voting securities, by contract or otherwise. 1.2 Argos Data means all clinical data that is produced or generated by Argos or its Related Parties during a Clinical Study for the Licensed Product. 1.3 Argos Indemnitees has the meaning set forth in Section 7.5.1. 1.4 Argos In-License means an agreement between Argos and a Third Party pursuant to which Argos has rights and obligations with respect to, or which otherwise Cover, the Licensed Product and is necessary to Develop, Commercialize and/or Manufacture the Licensed Product in the Field in the Green Cross Territory, including without limitation, the Existing Argos In-Licenses. 1.5 Argos Know-How means Know-How Controlled by Argos during the Term that is not in the public domain and is reasonably necessary or useful for Green Cross and its Related Parties to perform their obligations or exploit their rights under this Agreement with respect to products incorporating Argos Arcelis Personalized Immunotherapy Platform for the treatment of mRCC, as such platform is more particularly described on Schedule A attached hereto. For the avoidance of doubt, Argos Know-How shall include Argos Data, but shall not include any Know-How associated with or relating to Automated Systems, dendritic cell transfected with IL4 RNA for the treatment of unwanted autoimmune responses, anti-interferon alpha antibodies, soluble CD83 or regulatory T cells. 1.6 Argos Patent Rights means those Patent Rights Controlled by Argos during the Term that relate to Argos Arcelis Personalized Immunotherapy Platform for the treatment of mRCC and that are reasonably necessary or useful for Green Cross and its Related Parties to perform their obligations or exploit their rights under this Agreement with respect to the Licensed Product in the Field in the Green Cross Territory, including without limitation, any foreign counterparts in the Green Cross Territory to the Patent Rights set forth in Schedule B of this Agreement. For the avoidance of doubt, Argos Patent Rights shall not include patent rights associated with or relating to Automated Systems, dendritic cell transfected with IL4 RNA for the treatment of unwanted autoimmune responses, anti-interferon alpha antibodies, soluble CD83 or regulatory T cells. 1.7 Argos Technology means, collectively, Argos Know-How and Argos Patent Rights. 1.8 Argos Territory means all countries of the world other than the Green Cross Territory. 1.9 Argos Trademark has the meaning set forth in Section 8.8.2. 1.10 Automated Systems means the automated cellular and RNA systems used from time to time to Manufacture the Licensed Product, as such systems are generally described in Schedule C attached hereto. 1.11 Bankrupt Party has the meaning set forth in Section 9.2.3(c). 1.12 Calendar Quarter means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31; provided, that (a) the first Calendar Quarter of the Term shall begin on the Effective Date and end on the first to occur of March 31, June 30, September 30 or December 31 thereafter and the last Calendar Quarter of the Term shall end on the last day of the Term and (b) the first Calendar Quarter of the Royalty Term shall begin on the First Commercial Sale of the Licensed Product and end on the first to occur of March 31, June 30, September 30 or December 31 thereafter and the last Calendar Quarter of the Royalty Term shall end on the last day of such Royalty Term. 1.13 Calendar Year means each successive period of twelve (12) months commencing on January 1 and ending on December 31; provided, that (a) the first Calendar Year of the Term shall begin on the Effective Date and end on the first December 31 thereafter and the last Calendar Year of the Term shall end on the last day of the Term and (b) the first Calendar Year of the Royalty Term shall begin on the First Commercial Sale of the Licensed Product and end on the first December 31 thereafter and the last Calendar Year of the Term shall end on the last day of the Royalty Term. 1.14 Clinical Data means Argos Data and/or Green Cross

DEFINITIONS from License Agreement

THIS LICENSE AGREEMENT (the Agreement), effective as of August 9, 2013 (the Effective Date), is by and between Argos Therapeutics, Inc., a corporation organized and existing under the laws of Delaware (Argos) and Pharmstandard International S.A. (Luxembourg), a corporation organized and existing under the laws of Luxembourg and having its head office at 65, Boulevard Grande-Duchesse Charlotte, L-1331, Luxembourg (Pharmstandard).

DEFINITIONS. Unless specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, shall have the respective meanings set forth below: 1.1 Affiliate means a corporation or non-corporate business entity that, directly or indirectly, controls, is controlled by, or is under common control with the Person specified, for so long as such control continues. An entity will be regarded as in control of another entity if: (a) it owns, directly or indirectly, at least 50% of the voting securities or capital stock of such entity, or has other comparable ownership interest with respect to any entity other than a corporation; or (b) it possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of the corporation or non-corporate business entity, as applicable, whether through the ownership or control of voting securities, by contract or otherwise. 1.2 Argos Data means all clinical data that is produced or generated by Argos or its Related Parties during a Clinical Study for a Licensed Product. 1.3 Argos Follow-on Licensed Product has the meaning set forth in Section 2.5.3. 1.4 Argos Indemnitees has the meaning set forth in Section 7.5.1. 1.5 Argos In-License means an agreement between Argos and a Third Party pursuant to which Argos has rights and obligations with respect to, or which otherwise Cover, a Licensed Product and is necessary to Develop, Commercialize and/or Manufacture the Licensed Product in the Field in the Pharmstandard Territory, including without limitation, the Existing Argos In-Licenses. 1.6 Argos Know-How means Know-How Controlled by Argos during the Term that is reasonably necessary or useful for Pharmstandard and its Related Parties to perform their obligations or exploit their rights under this Agreement with respect to products incorporating Argos Arcelis Personalized Immunotherapy Platform for the treatment of tumors or pathogen infection, as such platform is more particularly described on Schedule A attached hereto. For the avoidance of doubt, Argos Know-How shall not include Argos Data, or Know-How associated with or relating to Automated Systems, dendritic cell transfected with IL4 RNA for the treatment of unwanted autoimmune responses, anti-interferon alpha antibodies, soluble CD83 or regulatory T cells. 1.7 Argos Patent Rights means those Patent Rights Controlled by Argos during the Term that relate to Argos Arcelis Personalized Immunotherapy Platform for the treatment of tumors or pathogen infection and that are reasonably necessary or useful for Pharmstandard and its Related Parties to perform their obligations or exploit their rights under this Agreement with respect to the Licensed Products in the Field in the Pharmstandard Territory. For the avoidance of doubt, (i) there are no Argos Patent Rights in the Pharmstandard Territory as of the Effective Date; and (ii) Argos Patent Rights shall not include patent rights associated with or relating to Automated Systems, dendritic cell transfected with IL4 RNA for the treatment of unwanted autoimmune responses, anti-interferon alpha antibodies, soluble CD83 or regulatory T cells. 1.8 Argos Technology means, collectively, Argos Know-How and Argos Patent Rights. 1.9 Argos Territory means all countries of the world other than the Pharmstandard Territory. 1.10 Argos Trademark has the meaning set forth in Section 8.8.2. 1.11 Automated Systems means the automated cellular and RNA systems used from time to time to Manufacture Licensed Products, as such systems are generally described in Schedule B attached hereto. 1.12 Bankrupt Party has the meaning set forth in Section 9.2.3(c). 1.13 Calendar Quarter means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31; provided, that (a) the first Calendar Quarter of the Term shall begin on the Effective Date and end on the first to occur of March 31, June 30, September 30 or December 31 thereafter and the last Calendar Quarter of the Term shall end on the last day of the Term and (b) the first Calendar Quarter of a Royalty Term for a Licensed Product in a country shall begin on the First Commercial Sale of the Licensed Product in such country and end on the first to occur of March 31, June 30, September 30 or December 31 thereafter and the last Calendar Quarter of a Royalty Term shall end on the last day of such Royalty Term. 1.14 Calendar Year means each successive period of twelve (12) months commencing on January 1 and ending on December 31; provided, that (a) the first Calendar Year of the Term shall begin on the Effective Date and end on the first December 31 thereafter and the last Calendar Year of the Term shall end on the last day of the Term and (b) the first Calendar Year of a Royalty Term for a Licensed Product in a country shall begin on the First Commercial Sale of the Licensed Product in such country and end on the first December 31 thereafter and t

DEFINITIONS from License Agreement

THIS LICENSE AGREEMENT (the Agreement), effective as of July 31, 2013 (the Effective Date), is by and between Argos Therapeutics, Inc., a corporation organized and existing under the laws of Delaware (Argos) and Green Cross Corp., a corporation organized and existing under the laws of Republic of Korea (Green Cross).

DEFINITIONS. Unless specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, shall have the respective meanings set forth below: 1.1 Affiliate means a corporation or non-corporate business entity that, directly or indirectly, controls, is controlled by, or is under common control with the Person specified, for so long as such control continues. An entity will be regarded as in control of another entity if: (a) it owns, directly or indirectly, at least 50% of the voting securities or capital stock of such entity, or has other comparable ownership interest with respect to any entity other than a corporation; or (b) it possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of the corporation or non-corporate business entity, as applicable, whether through the ownership or control of voting securities, by contract or otherwise. 1.2 Argos Data means all clinical data that is produced or generated by Argos or its Related Parties during a Clinical Study for the Licensed Product. 1.3 Argos Indemnitees has the meaning set forth in Section 7.5.1. 1.4 Argos In-License means an agreement between Argos and a Third Party pursuant to which Argos has rights and obligations with respect to, or which otherwise Cover, the Licensed Product and is necessary to Develop, Commercialize and/or Manufacture the Licensed Product in the Field in the Green Cross Territory, including without limitation, the Existing Argos In-Licenses. 1.5 Argos Know-How means Know-How Controlled by Argos during the Term that is not in the public domain and is reasonably necessary or useful for Green Cross and its Related Parties to perform their obligations or exploit their rights under this Agreement with respect to products incorporating Argos Arcelis Personalized Immunotherapy Platform for the treatment of mRCC, as such platform is more particularly described on Schedule A attached hereto. For the avoidance of doubt, Argos Know-How shall include Argos Data, but shall not include any Know-How associated with or relating to Automated Systems, dendritic cell transfected with IL4 RNA for the treatment of unwanted autoimmune responses, anti-interferon alpha antibodies, soluble CD83 or regulatory T cells. 1.6 Argos Patent Rights means those Patent Rights Controlled by Argos during the Term that relate to Argos Arcelis Personalized Immunotherapy Platform for the treatment of mRCC and that are reasonably necessary or useful for Green Cross and its Related Parties to perform their obligations or exploit their rights under this Agreement with respect to the Licensed Product in the Field in the Green Cross Territory, including without limitation, any foreign counterparts in the Green Cross Territory to the Patent Rights set forth in Schedule B of this Agreement. For the avoidance of doubt, Argos Patent Rights shall not include patent rights associated with or relating to Automated Systems, dendritic cell transfected with IL4 RNA for the treatment of unwanted autoimmune responses, anti-interferon alpha antibodies, soluble CD83 or regulatory T cells. 1.7 Argos Technology means, collectively, Argos Know-How and Argos Patent Rights. 1.8 Argos Territory means all countries of the world other than the Green Cross Territory. 1.9 Argos Trademark has the meaning set forth in Section 8.8.2. 1.10 Automated Systems means the automated cellular and RNA systems used from time to time to Manufacture the Licensed Product, as such systems are generally described in Schedule C attached hereto. 1.11 Bankrupt Party has the meaning set forth in Section 9.2.3(c). 1.12 Calendar Quarter means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31; provided, that (a) the first Calendar Quarter of the Term shall begin on the Effective Date and end on the first to occur of March 31, June 30, September 30 or December 31 thereafter and the last Calendar Quarter of the Term shall end on the last day of the Term and (b) the first Calendar Quarter of the Royalty Term shall begin on the First Commercial Sale of the Licensed Product and end on the first to occur of March 31, June 30, September 30 or December 31 thereafter and the last Calendar Quarter of the Royalty Term shall end on the last day of such Royalty Term. 1.13 Calendar Year means each successive period of twelve (12) months commencing on January 1 and ending on December 31; provided, that (a) the first Calendar Year of the Term shall begin on the Effective Date and end on the first December 31 thereafter and the last Calendar Year of the Term shall end on the last day of the Term and (b) the first Calendar Year of the Royalty Term shall begin on the First Commercial Sale of the Licensed Product and end on the first December 31 thereafter and the last Calendar Year of the Term shall end on the last day of the Royalty Term. 1.14 Clinical Data means Argos Data and/or Green Cross

DEFINITIONS from License Agreement

THIS LICENSE AGREEMENT (the Agreement), effective as of August 9, 2013 (the Effective Date), is by and between Argos Therapeutics, Inc., a corporation organized and existing under the laws of Delaware (Argos) and Pharmstandard International S.A. (Luxembourg), a corporation organized and existing under the laws of Luxembourg and having its head office at 65, Boulevard Grande-Duchesse Charlotte, L-1331, Luxembourg (Pharmstandard).

DEFINITIONS. Unless specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, shall have the respective meanings set forth below: 1.1 Affiliate means a corporation or non-corporate business entity that, directly or indirectly, controls, is controlled by, or is under common control with the Person specified, for so long as such control continues. An entity will be regarded as in control of another entity if: (a) it owns, directly or indirectly, at least 50% of the voting securities or capital stock of such entity, or has other comparable ownership interest with respect to any entity other than a corporation; or (b) it possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of the corporation or non-corporate business entity, as applicable, whether through the ownership or control of voting securities, by contract or otherwise. 1.2 Argos Data means all clinical data that is produced or generated by Argos or its Related Parties during a Clinical Study for a Licensed Product. 1.3 Argos Follow-on Licensed Product has the meaning set forth in Section 2.5.3. 1.4 Argos Indemnitees has the meaning set forth in Section 7.5.1. 1.5 Argos In-License means an agreement between Argos and a Third Party pursuant to which Argos has rights and obligations with respect to, or which otherwise Cover, a Licensed Product and is necessary to Develop, Commercialize and/or Manufacture the Licensed Product in the Field in the Pharmstandard Territory, including without limitation, the Existing Argos In-Licenses. 1.6 Argos Know-How means Know-How Controlled by Argos during the Term that is reasonably necessary or useful for Pharmstandard and its Related Parties to perform their obligations or exploit their rights under this Agreement with respect to products incorporating Argos Arcelis Personalized Immunotherapy Platform for the treatment of tumors or pathogen infection, as such platform is more particularly described on Schedule A attached hereto. For the avoidance of doubt, Argos Know-How shall not include Argos Data, or Know-How associated with or relating to Automated Systems, dendritic cell transfected with IL4 RNA for the treatment of unwanted autoimmune responses, anti-interferon alpha antibodies, soluble CD83 or regulatory T cells. 1.7 Argos Patent Rights means those Patent Rights Controlled by Argos during the Term that relate to Argos Arcelis Personalized Immunotherapy Platform for the treatment of tumors or pathogen infection and that are reasonably necessary or useful for Pharmstandard and its Related Parties to perform their obligations or exploit their rights under this Agreement with respect to the Licensed Products in the Field in the Pharmstandard Territory. For the avoidance of doubt, (i) there are no Argos Patent Rights in the Pharmstandard Territory as of the Effective Date; and (ii) Argos Patent Rights shall not include patent rights associated with or relating to Automated Systems, dendritic cell transfected with IL4 RNA for the treatment of unwanted autoimmune responses, anti-interferon alpha antibodies, soluble CD83 or regulatory T cells. 1.8 Argos Technology means, collectively, Argos Know-How and Argos Patent Rights. 1.9 Argos Territory means all countries of the world other than the Pharmstandard Territory. 1.10 Argos Trademark has the meaning set forth in Section 8.8.2. 1.11 Automated Systems means the automated cellular and RNA systems used from time to time to Manufacture Licensed Products, as such systems are generally described in Schedule B attached hereto. 1.12 Bankrupt Party has the meaning set forth in Section 9.2.3(c). 1.13 Calendar Quarter means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31; provided, that (a) the first Calendar Quarter of the Term shall begin on the Effective Date and end on the first to occur of March 31, June 30, September 30 or December 31 thereafter and the last Calendar Quarter of the Term shall end on the last day of the Term and (b) the first Calendar Quarter of a Royalty Term for a Licensed Product in a country shall begin on the First Commercial Sale of the Licensed Product in such country and end on the first to occur of March 31, June 30, September 30 or December 31 thereafter and the last Calendar Quarter of a Royalty Term shall end on the last day of such Royalty Term. 1.14 Calendar Year means each successive period of twelve (12) months commencing on January 1 and ending on December 31; provided, that (a) the first Calendar Year of the Term shall begin on the Effective Date and end on the first December 31 thereafter and the last Calendar Year of the Term shall end on the last day of the Term and (b) the first Calendar Year of a Royalty Term for a Licensed Product in a country shall begin on the First Commercial Sale of the Licensed Product in such country and end on the first December 31 thereafter and t

DEFINITIONS from License and Collaboration Agreement

THIS AGREEMENT, effective as of June 19, 2008 (the Effective Date), by and between Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware (Alnylam) and Kyowa Hakko Kogyo Co., Ltd., a corporation organized and existing under the laws of Japan (Kyowa Hakko).

DEFINITIONS. Unless specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, shall have the respective meanings set forth below: 1.1 Affiliate means, with respect to a Party, (a) any corporation or business entity of which fifty percent (50%) or more of the securities or other ownership interests representing the equity, the voting stock or general partnership interest are owned, controlled or held, directly or indirectly, by such Party; (b) any corporation or business entity, which, directly or indirectly, owns, controls or holds fifty percent (50%) (or the maximum ownership interest permitted by law) or more of the securities or other ownership interests representing the equity, the voting stock or, if applicable, the general partnership interest, of such Party; or (c) any corporation or business entity, fifty percent (50%) or more of the securities or other ownership interests representing the equity of which is directly or indirectly owned, controlled or held by the same corporation, business entity or security holders, or holders of ownership interests, that own, control or hold fifty percent (50%) or more of the securities or other ownership interests representing the equity or the voting stock of such Party. For the avoidance of doubt, Regulus Therapeutics LLC shall not be considered an Affiliate of Alnylam for purposes hereof. 1.2 Alnylam Collaboration IP means (a) any improvement, discovery or Know-How, patentable or otherwise, first identified, discovered or developed solely by employees of Alnylam or its Affiliates or other persons not employed by Kyowa Hakko acting on behalf of Alnylam, in the conduct of the Collaboration, and (b) any Patent Rights that claim or cover such improvements, discoveries or Know-How and are Controlled by Alnylam at any time during the Term. Alnylam Collaboration IP excludes Alnylams interest in Joint Collaboration IP. 1.3 Alnylam Indemnitees has the meaning set forth in Section 9.5.1. 1.4 Alnylam In-License means an agreement between Alnylam and a Third Party pursuant to which Alnylam has rights and obligations with respect to, or which otherwise Cover, a Licensed Product and is necessary to Develop, Commercialize and/or Manufacture the Licensed Product in the Field, including without limitation, the Existing Alnylam In-Licenses. 1.5 Alnylam Know-How means Know-How Controlled by Alnylam during the Term that is reasonably necessary or useful for Kyowa Hakko and its Related Parties to perform their obligations or exploit their rights under this Agreement with respect to the Licensed Product (other than Alnylams rights in Joint Collaboration IP and Alnylam Collaboration IP). 1.6 Alnylam Patent Rights means those Patent Rights Controlled by Alnylam during the Term that are reasonably necessary or useful for Kyowa Hakko and its Related Parties to perform their obligations or exploit their rights under this Agreement with respect to the Licensed Product (other than Alnylams rights in Joint Collaboration IP and Alnylam Collaboration IP), including without limitation, the Patent Rights set forth in Schedule 1.6A of this Agreement. For clarity, Schedule 1.6B of this Agreement includes additional Patent Rights which will be included in Alnylam Patent Rights at no additional cost to Kyowa Hakko to the extent they are Controlled by Alnylam if they become reasonably necessary or useful for Kyowa Hakko and its Related Parties to perform their obligations or exploit their rights under this Agreement with respect to the Licensed Product (other than Alnylams rights in Joint Collaboration IP and Alnylam Collaboration IP), including, by way of example, as the result of the Development of a Replacement Product or a Successor Product. 1.7 Alnylam Technology means, collectively, Alnylam Know-How, Alnylam Patent Rights, Alnylam Collaboration IP and Alnylams interest in Joint Collaboration IP. 1.8 Alnylam Territory means all countries of the world other than the Kyowa Hakko Territory. 1.9 Alnylam Trademark has the meaning set forth in Section 10.9(b). 1.10 Antisense Product means a single-stranded oligonucleotide or analog thereof having a specific sequence that inhibits protein synthesis at the nucleic acid level by specifically binding to the sequence of a messenger or viral ribonucleic acid (RNA) by base-pairing, thus causing selective inhibition of gene expression. 1.11 API Bulk Drug Substance means the Licensed Product in bulk form manufactured for use as an active pharmaceutical ingredient. 1.12 Bankrupt Party has the meaning set forth in Section 11.2.4(d). 1.13 Clinical Study (organization) values">Bridging Clinical Study means a human clinical study conducted [**] that is designed to demonstrate the [**] generated in a study of [**] treated with the Licensed Product to [**] of the Licensed Product in [**]. Data to evaluate in such a study might include pharmacokinetics, efficacy and/or additional safety data. The Bridging Clinical Study shall be designed such that, if its endpoints a